This raises the question of a potential synergistic effect between CD25 Mab and the BCL-2 inhibitor venetoclax, especially since we found CD25+ AML clusters in all four patients treated with HMA-VEN and CD25 was more highly expressed on LSCs and immature AML cells. The gene discussed is BCL2; the disease is acute myeloid leukemia.